A Phase 1/2 interventional study of Guadecitabine in MDS, CMML and AML, sponsored by Astex Pharmaceuticals, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-23.
Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML participants while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment.
Once the biologically effective dose (BED) and maximum tolerated dose (MTD) is determined in the Dose Escalation Segment, the Dose Expansion Segment will randomize participants with MDS, treatment naïve elderly acute myeloid leukemia (AML), and relapsed/refractory AML participants to receive the BED or MTD dose. Relapsed/refractory AML participants may also receive SGI-110 on a daily x 10 schedule based on the total dose per cycle evaluated in the Dose-escalation Segment using the 5-daily regimen.
Astex Pharmaceuticals, Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men or women, 18 years of age or older, with a confirmed diagnosis of international prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS including Chronic Myelomonocytic Leukemia (CMML) or AML.
In the Dose Expansion Segment, hypomethylating agent (HMA) treatment-naïve MDS participants (including CMML), and intermediate-2 or high-risk MDS participant (including CMML) relapsed or refractory to prior HMA treatment are allowed, and treatment-naïve AML participants who is at least 65 years of age will be allowed if they also have at least one of the following criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received starting dose of guadecitabine 3 milligrams per meter square (mg/m\^2), subcutaneously (SC), daily from Days 1-5, of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m\^2 for subsequent cycles until development of toxicity or disease progression.
Drug: Guadecitabine
Participants received starting dose of guadecitabine 6 mg/m\^2, SC, once weekly on Days 1, 8 and 15, of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m\^2 for subsequent cycles until development of toxicity or disease progression.
Drug: Guadecitabine
Participants received starting dose of guadecitabine 60 mg/m\^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18, of a 28-day cycle. The dose was subsequently increased to 90 mg/m\^2 for subsequent cycles until development of toxicity or disease progression.
Drug: Guadecitabine
Participants received guadecitabine 60 mg/m\^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with diagnosis relapsed/refractory (r/r) AML.
Drug: Guadecitabine
Participants received guadecitabine 90 mg/m\^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r AML.
Drug: Guadecitabine
Participants received guadecitabine 60 mg/m\^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of r/r AML.
Drug: Guadecitabine
Participants received guadecitabine 60 mg/m\^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of treatment naïve (TN) AML.
Drug: Guadecitabine
Participants received guadecitabine 90 mg/m\^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of TN AML.
Drug: Guadecitabine
Participants received guadecitabine 60 mg/m\^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of TN AML.
Drug: Guadecitabine
Participants received guadecitabine 60 mg/m\^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r Myelodysplastic Syndromes (MDS).
Drug: Guadecitabine
Participants received guadecitabine 90 mg/m\^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r MDS.
Drug: Guadecitabine
Participants received guadecitabine 60 mg/m\^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS.
Drug: Guadecitabine
Participants received guadecitabine 90 mg/m\^2, SC daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS.
Drug: Guadecitabine
Subcutaneous injection
Also known as: SGI-110
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Time frame: Cycle 1 Day 8
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Time frame: Cycle 1 Day 15
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Time frame: Cycle 1 Day 22
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Time frame: Cycle 2 Day 1
Dose Escalation Phase-Maximum Tolerated Dose (MTD): Number of Participants With Dose Limiting Toxicity (DLT)
The MTD was defined as the largest dose for which less than 33% of subjects experienced a dose limiting toxicity (DLT) during Cycle 1 of guadecitabine administration at each dose level. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
Time frame: From the start of study treatment up to 30 days post treatment (Up to approximately 46 months)
Dose Expansion (DE) Phase- r/r AML, TN AML: Composite Complete Response (CRc) Rate
Composite complete response (CRc) rate is defined as the percentage of participants whose best response is complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) after treatment with study drug. CR as per AML response criteria is defined as peripheral blood absolute neutrophil count (ANC) ≥1.0×10\^9/L, Platelets ≥100×10\^9/L, independence from red blood cell (RBC) and platelet transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow.
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion (DE) Phase- r/r MDS, TN MDS: Overall Response Rate (ORR)
ORR is defined as percentage of participants with complete response(CR), partial response(PR), marrow complete response(mCR) and haematological improvement(HI). CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10\^9/L and platelet count ≥100 ×10\^9/L and normal BM with marrow blasts \>5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or red blood cells transfusion independence, platelet response (HI-P): absolute increase of platelet count from \<20 to \>20×10\^9/L and by at least 100%,/if more than 20×10\^9/L, by an absolute increase of 30×10\^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, and by an absolute increase ≥0.5×10\^9/L.
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation Phase: Response Rate in AML Participants
Response rate for AML participants was assessed by Modified International Working Group (IWG) 2003 response criteria with complete response (CR), complete response with incomplete platelet recovery (CRp), CR with incomplete blood count recovery(CRi), and partial response (PR). CR: absolute neutrophil count (ANC) \>1.0×10\^9/L, platelets ≥100×10\^9/L, independence from RBC and platelet transfusions, no or \<5% myeloblasts in bone marrow(BM). CRp: ANC \>1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions, no or \<5% myeloblasts in BM. CRi: ANC \<1.0×10\^9/L, no or \<5% myeloblasts in BM. PR: ANC \>1.0×10\^9/L, Platelets ≥100×10\^9/L, no or decrease of ≥50% in myeloblasts to 5-25% in BM.
Time frame: At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation Phase: Response Rate in MDS Participants
Response rate for MDS participants was assessed by IWG 2006 Response Criteria with CR, PR, marrow complete response(mCR) and HI. CR: normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L; normal BM with persistent marrow blasts ≤5%; persistent dysplasia. PR: Normal peripheral counts with granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal BM with blasts \>5% but reduced by 50% or more. mCR: reduction of BM blasts to ≤5% without normalization of peripheral counts.
Time frame: At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation and Dose Expansion Phase- r/r AML, TN AML: Duration of Response
Duration of response (in number of days) was calculated from the first time a complete response (CR, CRp, or CRi) was observed to time of relapse defined as the earliest time point whereby BM blasts or peripheral blood blasts become ≥5% and stayed at that level in subsequent visits while participants were still on study. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow.
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation Phase: Hematologic Improvement Rate in MDS
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Duration of Response
DOR was calculated from first time a response category (CR, PR, mCR, or HI) was achieved until response category was no longer met or the last available time point, whichever occurred first. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10\^9/L and platelet count ≥100 ×10\^9/L and normal BM with marrow blasts \>5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from \<20 to \>20×10\^9/L by at least 100%,/if more than 20×10\^9/L, by absolute increase of 30×10\^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10\^9/L.
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation r/r AML, TN AML: Time to Response
Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (cycle 1 day 1 {C1D1}) to the first day of response. Composite complete response rate (CRc = CR + CRp + CRi), which is an overall complete response assessment including CR, CR with incomplete platelet recovery (CRp) and CR with incomplete blood count recovery (CRi). CRc rate, was defined as the number of participants who achieved a response status of CR, CRp, or CRi divided by the total number of participants included in the efficacy dataset. The CR rate is defined as the number of participants whose best response is CR divided by the total number of participants included in the efficacy dataset.
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion Phase- r/r MDS, TN MDS: Time to Response
Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (C1D1) to the first day of response. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10\^9/L and platelet count ≥100 ×10\^9/L and normal BM with marrow blasts \>5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from \<20 to \>20×10\^9/L by at least 100%,/if more than 20×10\^9/L, by absolute increase of 30×10\^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10\^9/L.
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Number of Participants With Dose Limiting Toxicities (DLT) Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
DLT was defined using CTCAE v4.0. Toxicities were considered related to SGI-110 if it cannot be explained by underlying disease, intercurrent illness or concomitant medications. Any related Grade 3 or 4 non-hematologic toxicity except Grade 3 or 4 nausea/vomiting that is controllable by anti-emetics or diarrhea controllable by optimal therapy. Grade 3 laboratory investigations other than serum creatinine, bilirubin, AST or ALT were not considered a DLT unless they are associated with clinical manifestations. Study-drug related Grade 4 thrombocytopenia and Febrile neutropenia that was not present at study entry, and not resolve within 7 days, and is not related to underlying disease. Prolonged myelosuppression or pancytopenia with hypocellular bone marrow and no marrow blasts lasting for 6 weeks or more that is not related to disease progression. Any toxicity that results in treatment delays of \> 4 weeks. Data is reported for any AE occurring during Cycle 1 (each cycle = 28 days).
Time frame: Cycle 1 (each cycle = 28 days)
Dose Escalation and Dose Expansion Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent AEs are defined as events that first occurred or worsened after the first dose of study drug given on C1D1 until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML, whichever occurs first, with the following exceptions: events that occurred after 30 days beyond the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML was considered treatment-emergent if the events are both serious and related to the study treatment.
Time frame: From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With Abnormal Laboratory Values Reported as Adverse Events
Time frame: From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation: Maximum Observed Plasma Concentration (Cmax ) of SGI-110 and Decitabine
Time frame: Days 1, 5 and 8
Dose Escalation: Minimum Observed Plasma Concentration (Cmin)
Time frame: Days 5 and 8
Dose Escalation: Area Under the Curve to Infinity (AUC0-inf)
Time frame: Days 1, 5 and 8
Dose Escalation and DE Phase- r/r MDS, TN MDS: Time to AML or Death
Time to AML or death was defined as the number of days from the date the subject received the first dose of guadecitabine (C1D1) to the date of death or the date of MDS/ chronic myelomonocytic leukemia (CMML) progression to AML, whichever occurred earlier. Time to AML or death was evaluated using the Kaplan-Meier method, with the time censored on the last date of contact if a participant was still alive without progression to AML.
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Overall Survival
OS was defined as the number of days from the day the participant received the first dose of guadecitabine to the date of death (regardless of cause).
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation: Number of Participants Achieving Blood and Platelet Transfusions
Time frame: Cycle 1, Day 1 through 30 days after the last dose of study drug (up to approximately 46 months)
DE Phase- r/r AML, TN AML: Percentage of Participants With Cr, CRp and PR
CR is defined absolute neutrophil count (ANC) \>1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRp is defined ANC \>1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi is defined as ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow. PR is defined as ANC \>1.0×10\^9/L, Platelets ≥100×10\^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Percentage of Participants With CR, PR, mCR and HI
CR is defined ANC \>1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRp is defined ANC \>1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi is defined as ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow. PR is defined as ANC \>1.0×10\^9/L, Platelets ≥100×10\^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Blood Transfusion Independence for 8 or 16-weeks
Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Time frame: Weeks 8 and 16
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Platelet Transfusion Independence for 8 or 16-weeks
Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Time frame: Weeks 8 and 16
| Milestone | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 44 | 35 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety data set | 44 | 34 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 44 | 35 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 27 | 26 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 5 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Hematopoietic cell transplant (hct) | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 25 | 28 | 55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety data set | 0 | 0 | 0 | 24 | 26 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 24 | 27 | 55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 14 | 16 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 4 | 3 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Hct | 0 | 0 | 0 | 5 | 3 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 28 | 53 | 0 | 0 | 0 | 0 |
| Safety data set | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 27 | 52 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 26 | 50 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 11 | 17 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Bone marrow (bm)/stem cell transplant | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 6 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 27 | 28 | 23 |
| Safety data set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 27 | 27 | 22 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 25 | 27 | 20 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 9 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 3 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 3 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 1 | 2 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 | 3 | 5 |
| Withdrew: Bm/stem cell transplant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 6 | 4 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 1 |
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
| percent change | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation | -16.143 ± 12.692 | -4.362 ± 5.484 | -10.574 ± 8.444 |
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
| percent change | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation | -10.359 ± 9.837 | -5.312 ± 5.796 | -17.540 ± 9.207 |
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
| percent change | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation | -6.325 ± 7.477 | -4.777 ± 4.765 | -16.959 ± 10.112 |
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
| percent change | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation | -2.805 ± 4.249 | -1.860 ± 3.844 | -13.346 ± 6.039 |
The MTD was defined as the largest dose for which less than 33% of subjects experienced a dose limiting toxicity (DLT) during Cycle 1 of guadecitabine administration at each dose level. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
| Participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| DLT | 2 | 0 | 0 |
| Adverse Event (AE) | 44 | 34 | 15 |
Composite complete response (CRc) rate is defined as the percentage of participants whose best response is complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) after treatment with study drug. CR as per AML response criteria is defined as peripheral blood absolute neutrophil count (ANC) ≥1.0×10\^9/L, Platelets ≥100×10\^9/L, independence from red blood cell (RBC) and platelet transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow.
| percentage of participants | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) |
|---|---|---|---|---|---|---|
| Dose Expansion (DE) Phase- r/r AML, TN AML: Composite Complete Response (CRc) Rate | 12.5 (2.7 to 32.4) | 19.2 (6.6 to 39.4) | 30.2 (18.3 to 44.3) | 54.2 (32.8 to 74.4) | 59.3 (38.8 to 77.6) | 50.0 (35.8 to 64.2) |
ORR is defined as percentage of participants with complete response(CR), partial response(PR), marrow complete response(mCR) and haematological improvement(HI). CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10\^9/L and platelet count ≥100 ×10\^9/L and normal BM with marrow blasts \>5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or red blood cells transfusion independence, platelet response (HI-P): absolute increase of platelet count from \<20 to \>20×10\^9/L and by at least 100%,/if more than 20×10\^9/L, by an absolute increase of 30×10\^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, and by an absolute increase ≥0.5×10\^9/L.
| percentage of participants | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|
| Dose Expansion (DE) Phase- r/r MDS, TN MDS: Overall Response Rate (ORR) | 31 (14.3 to 51.8) | 56 (35.3 to 74.5) | 48 (28.7 to 68.1) | 55 (32.2 to 75.6) |
Response rate for AML participants was assessed by Modified International Working Group (IWG) 2003 response criteria with complete response (CR), complete response with incomplete platelet recovery (CRp), CR with incomplete blood count recovery(CRi), and partial response (PR). CR: absolute neutrophil count (ANC) \>1.0×10\^9/L, platelets ≥100×10\^9/L, independence from RBC and platelet transfusions, no or \<5% myeloblasts in bone marrow(BM). CRp: ANC \>1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions, no or \<5% myeloblasts in BM. CRi: ANC \<1.0×10\^9/L, no or \<5% myeloblasts in BM. PR: ANC \>1.0×10\^9/L, Platelets ≥100×10\^9/L, no or decrease of ≥50% in myeloblasts to 5-25% in BM.
| percentage of participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase: Response Rate in AML Participants | 11.4 (3.2 to 26.7) | 7.1 (0.9 to 23.5) | 0.0 (0.0 to 28.5) |
Response rate for MDS participants was assessed by IWG 2006 Response Criteria with CR, PR, marrow complete response(mCR) and HI. CR: normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L; normal BM with persistent marrow blasts ≤5%; persistent dysplasia. PR: Normal peripheral counts with granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal BM with blasts \>5% but reduced by 50% or more. mCR: reduction of BM blasts to ≤5% without normalization of peripheral counts.
| percentage of participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase: Response Rate in MDS Participants | 22.2 (2.8 to 60.0) | 50.0 (11.8 to 88.2) | 25.0 (0.6 to 80.6) |
Duration of response (in number of days) was calculated from the first time a complete response (CR, CRp, or CRi) was observed to time of relapse defined as the earliest time point whereby BM blasts or peripheral blood blasts become ≥5% and stayed at that level in subsequent visits while participants were still on study. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow.
| days | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Dose Expansion Phase- r/r AML, TN AML: Duration of Response | 213.0 (47 to 350) | 300.0 (42 to 558) | — | 816.0 (15 to 880) | 112.0 (55 to 879) | 233.0 (42 to 898) | 237.0 (8 to 1068) | 185.5 (16 to 948) | 269.5 (40 to 669) |
| percentage of participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation Phase: Hematologic Improvement Rate in MDS | 0.0 (0.0 to 33.6) | 50.0 (11.8 to 88.2) | 25.0 (0.6 to 80.6) |
DOR was calculated from first time a response category (CR, PR, mCR, or HI) was achieved until response category was no longer met or the last available time point, whichever occurred first. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10\^9/L and platelet count ≥100 ×10\^9/L and normal BM with marrow blasts \>5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from \<20 to \>20×10\^9/L by at least 100%,/if more than 20×10\^9/L, by absolute increase of 30×10\^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10\^9/L.
| days | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|
| CR+PR+mCR | 295.0 (101 to 529) | 207.0 (42 to 984) | 103.0 (35 to 1144) | 165.0 (42 to 958) |
| HI | 202.5 (91 to 574) | 193.0 (71 to 1050) | 227.0 (89 to 525) | 127.0 (81 to 1087) |
Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (cycle 1 day 1 {C1D1}) to the first day of response. Composite complete response rate (CRc = CR + CRp + CRi), which is an overall complete response assessment including CR, CR with incomplete platelet recovery (CRp) and CR with incomplete blood count recovery (CRi). CRc rate, was defined as the number of participants who achieved a response status of CR, CRp, or CRi divided by the total number of participants included in the efficacy dataset. The CR rate is defined as the number of participants whose best response is CR divided by the total number of participants included in the efficacy dataset.
| days | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Dose Escalation r/r AML, TN AML: Time to Response | 106.0 (106 to 147) | 55.5 (27 to 84) | — |
Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (C1D1) to the first day of response. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10\^9/L, platelet count ≥100×10\^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10\^9/L and platelet count ≥100 ×10\^9/L and normal BM with marrow blasts \>5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from \<20 to \>20×10\^9/L by at least 100%,/if more than 20×10\^9/L, by absolute increase of 30×10\^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10\^9/L.
| days | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|
| CR+PR+mCR | 27.0 (25 to 512) | 68.0 (23 to 189) | 196.0 (24 to 245) | 133 (47 to 392) |
| HI | 108.0 (5 to 173) | 58.0 (27 to 277) | 64.5 (0 to 364) | 49.0 (27 to 119) |
DLT was defined using CTCAE v4.0. Toxicities were considered related to SGI-110 if it cannot be explained by underlying disease, intercurrent illness or concomitant medications. Any related Grade 3 or 4 non-hematologic toxicity except Grade 3 or 4 nausea/vomiting that is controllable by anti-emetics or diarrhea controllable by optimal therapy. Grade 3 laboratory investigations other than serum creatinine, bilirubin, AST or ALT were not considered a DLT unless they are associated with clinical manifestations. Study-drug related Grade 4 thrombocytopenia and Febrile neutropenia that was not present at study entry, and not resolve within 7 days, and is not related to underlying disease. Prolonged myelosuppression or pancytopenia with hypocellular bone marrow and no marrow blasts lasting for 6 weeks or more that is not related to disease progression. Any toxicity that results in treatment delays of \> 4 weeks. Data is reported for any AE occurring during Cycle 1 (each cycle = 28 days).
| Participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLT) Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | 2 | 0 | 0 |
Treatment-emergent AEs are defined as events that first occurred or worsened after the first dose of study drug given on C1D1 until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML, whichever occurs first, with the following exceptions: events that occurred after 30 days beyond the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML was considered treatment-emergent if the events are both serious and related to the study treatment.
| Participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Dose Expansion Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs) | 44 | 34 | 15 | 24 | 26 | 53 | 24 | 27 | 52 | 26 | 27 | 27 | 22 |
| Participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine Aminotransferase Increased | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 6 | 0 | 2 | 1 | 0 |
| Hypoalbuminaemia | 6 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 0 | 2 | 2 | 1 |
| Blood Alkaline Phosphatase Increased | 2 | 1 | 0 | 0 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood Alkaline Phosphatase Decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase Increased | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 0 | 0 | 1 | 1 |
| Blood Creatinine Increased | 3 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 4 | 0 | 2 | 2 | 1 |
| Blood Creatinine Decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Magnesium Increased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Potassium Increased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 1 | 0 |
| Hyperbilirubinaemia | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| ng/mL | Dose Escalation: Regimen 1: Once Daily - 3 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 9 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 18 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 36 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - SGI-110 - 60 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 90 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 125 mg/m^2 | Dose Escalation: Regimen 2A: Once Weekly- 6 mg/m^2 | Dose Escalation: Regimen 2A: Once Weekly- 18 mg/m^2 | Dose Escalation: 10. Regimen 2A: Once Weekly- 36 mg/m^2 | Dose Escalation: Regimen 2A: Once Weekly - 60 mg/m^2 | Dose Escalation: Regimen 2A: Once Weekly - 90 mg/m^2 | Dose Escalation: Regimen 2A: Once Weekly - 125 mg/m^2 | Dose Escalation: Regimen 2B: Twice Weekly - 60 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGI-110: Day 1 | 6.69 ± 72.9 | 19.1 ± 43.5 | 45.7 ± 57.9 | 106 ± 129 | 121 ± 31.9 | 155 ± 34.6 | 178 ± 46.2 | 11.7 ± 65.7 | 37.4 ± 73.4 | 61.9 ± 44.5 | 101 ± 51.0 | 100 ± 30.2 | 219 ± 36.5 | 106 ± 29.9 |
| SGI-110: Day 5 | 11.1 ± 65.8 | 30.7 ± 42.5 | 45.2 ± 43.4 | 72.7 ± 41.1 | 120 ± 31.7 | 205 ± 34.9 | 173 ± 36.7 | — | — | — | — | — | — | — |
| SGI-110: Day 8 | — | — | — | — | — | — | — | 10.7 ± 60.7 | 18.1 ± 99.3 | 66.3 ± 63.8 | 107 ± 40.0 | 118 ± 27.8 | 187 ± 40.9 | — |
| Decitabine: Day 1 | 1.27 ± 30.5 | 2.54 ± 18.5 | 8.18 ± 56.9 | 13.9 ± 60.4 | 23.7 ± 79.8 | 42.0 ± 40.0 | 61.5 ± 37.4 | 3.05 ± 48.4 | 8.20 ± 52.7 | 17.1 ± 55.9 | 16.7 ± 47.0 | 30.1 ± 41.3 | 65.9 ± 50.0 | 26.1 ± 83.2 |
| Decitabine: Day 5 | 1.67 ± 54.7 | 3.52 ± 27.4 | 10.3 ± 65.1 | 16.7 ± 37.6 | 22.7 ± 69.9 | 53.6 ± 37.4 | 59.1 ± 30.5 | — | — | — | — | — | — | — |
| Decitabine: Day 8 | — | — | — | — | — | — | — | 2.78 ± 43.8 | 6.92 ± 79.5 | 12.7 ± 41.8 | 19.0 ± 55.8 | 35.0 ± 45.4 | 53.2 ± 39.5 | — |
| ng/mL | Dose Escalation: Regimen 1: Once Daily - 3 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 9 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 18 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 36 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 60 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 90 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 125 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 6 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 18 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 36 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 60 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 90 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 125 mg/m^2 | Dose Escalation: Regimen 2B: Once Daily - 60 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGI-110: Day 5 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | — | — | — | — | — | — | — |
| SGI-110: Day 8 | — | — | — | — | — | — | — | NA ± 224 | NA ± NA | NA ± NA | NA ± 200 | NA ± NA | NA ± NA | — |
| ng*hr/mL | Dose Escalation: Regimen 1: Once Daily - 3 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 9 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 18 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 36 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - SGI-110 - 60 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 90 mg/m^2 | Dose Escalation: Regimen 1: Once Daily - 125 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 6 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 18 mg/m^2 | Dose Escalation: 10. Regimen 2A: Once Daily - 36 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 60 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 90 mg/m^2 | Dose Escalation: Regimen 2A: Once Daily - 125 mg/m^2 | Dose Escalation: Regimen 2B: Once Daily - 60 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGI-110: Day 1 | 12.1 ± 71.5 | 45.2 ± 23.9 | 102 ± 42.7 | 211 ± 55.8 | 410 ± 25.8 | 528 ± 26.8 | 648 ± 31.3 | 21.4 ± 65.4 | 99.8 ± 25.2 | 182 ± 19.5 | 327 ± 48.9 | 331 ± 23.1 | 636 ± 40.2 | 328 ± 38.4 |
| SGI-110: Day 5 | 26.5 ± 5.87 | 63.5 ± 13.7 | 112 ± 29.8 | 226 ± 35.0 | 354 ± 13.8 | 423 ± 46.0 | 658 ± 26.9 | — | — | — | — | — | — | — |
| SGI-110: Day 8 | — | — | — | — | — | — | — | 17.9 ± 42.1 | 58.0 ± 15.0 | 227 ± 50.5 | 371 ± 15.2 | 383 ± 27.4 | 675 ± 45.1 | — |
Time to AML or death was defined as the number of days from the date the subject received the first dose of guadecitabine (C1D1) to the date of death or the date of MDS/ chronic myelomonocytic leukemia (CMML) progression to AML, whichever occurred earlier. Time to AML or death was evaluated using the Kaplan-Meier method, with the time censored on the last date of contact if a participant was still alive without progression to AML.
| days | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|
| Dose Escalation and DE Phase- r/r MDS, TN MDS: Time to AML or Death | 244.5 (165.0 to 581.0) | 275.0 (197.0 to 585.0) | 373.0 (212.0 to NA) | 273 (164.0 to 622.0) | 276 (175.0 to 436.0) | 680 (402.0 to 848.0) | 542.5 (224.0 to NA) |
OS was defined as the number of days from the day the participant received the first dose of guadecitabine to the date of death (regardless of cause).
| days | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Overall Survival | 124 (82.0 to 181.0) | 186.5 (115.0 to 236.0) | 212.0 (111.0 to 304.0) | 172 (142.0 to 254.0) | 214 (169.0 to 269.0) | — | — | — | — | 273 (199.0 to 622.0) | 370 (253.0 to 447.0) | 771 (460.0 to 1017.0) | 558 (269.0 to NA) |
| percentage of participants | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly |
|---|---|---|---|
| (Maintaining/achieving platelet transfusion independence) | 100 | 89 | 75 |
| (Maintaining/achieving RBC transfusion independence) | 100 | 79 | 89 |
CR is defined absolute neutrophil count (ANC) \>1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRp is defined ANC \>1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi is defined as ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow. PR is defined as ANC \>1.0×10\^9/L, Platelets ≥100×10\^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
| percentage of participants | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) |
|---|---|---|---|---|---|---|
| CR | 8.3 | 7.7 | 18.9 | 37.5 | 40.7 | 32.7 |
| CRi | 4.2 | 11.5 | 3.8 | 16.7 | 11.1 | 7.7 |
| CRp | 0 | 0 | 7.5 | 0 | 7.4 | 9.6 |
| PR | 0 | 0 | 0 | 4.2 | 3.7 | 1.9 |
CR is defined ANC \>1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRp is defined ANC \>1.0×10\^9/L, Platelets \<100×10\^9/L, independence from RBC transfusions over the past week, no myeloblasts and \<5% myeloblasts in bone marrow. CRi is defined as ANC \<1.0×10\^9/L, no myeloblasts and \<5% myeloblasts in bone marrow. PR is defined as ANC \>1.0×10\^9/L, Platelets ≥100×10\^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
| percentage of participants | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|
| CR+PR+mCR | 19 | 44 | 26 | 50 |
| HI | 23 | 33 | 44 | 41 |
Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
| Participants | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|
| RBC Independence for Week 8 | 1 | 4 | 6 | 4 |
| RBC Independence for Week 16 | 0 | 3 | 5 | 1 |
Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
| Participants | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|
| Platelet Independence for Week 8 | 0 | 5 | 3 | 3 |
| Platelet Independence for Week 16 | 0 | 2 | 2 | 2 |
Collected over From first dose of study drug up to 30 days post study treatment (up to 46 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | 5/44 (11.4%) | 33/44 (75%) | 44/44 (100%) |
| Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | 4/35 (11.4%) | 28/34 (82.4%) | 34/34 (100%) |
| Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | 0/15 (0%) | 8/15 (53.3%) | 15/15 (100%) |
| Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | 4/25 (16%) | 19/24 (79.2%) | 24/24 (100%) |
| Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | 3/28 (10.7%) | 21/26 (80.8%) | 26/26 (100%) |
| Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | 10/55 (18.2%) | 44/53 (83%) | 53/53 (100%) |
| Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | 4/24 (16.7%) | 21/24 (87.5%) | 24/24 (100%) |
| Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | 7/27 (25.9%) | 24/27 (88.9%) | 27/27 (100%) |
| Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | 11/52 (21.2%) | 45/52 (86.5%) | 52/52 (100%) |
| Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | 2/26 (7.7%) | 17/26 (65.4%) | 26/26 (100%) |
| Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | 4/27 (14.8%) | 22/27 (81.5%) | 27/27 (100%) |
| Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | 1/27 (3.7%) | 17/27 (63%) | 27/27 (100%) |
| Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | 2/22 (9.1%) | 17/22 (77.3%) | 22/22 (100%) |
| Event | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 13/44 | 11/34 | 5/15 | 9/24 | 10/26 | 28/53 | 12/24 | 15/27 | 25/52 | 9/26 | 11/27 | 7/27 | 9/22 |
| PneumoniaInfections and infestations | 15/44 | 8/34 | 3/15 | 5/24 | 9/26 | 17/53 | 4/24 | 10/27 | 16/52 | 4/26 | 10/27 | 7/27 | 4/22 |
| SepsisInfections and infestations | 8/44 | 6/34 | 2/15 | 2/24 | 2/26 | 11/53 | 2/24 | 6/27 | 14/52 | 2/26 | 4/27 | 0/27 | 3/22 |
| CellulitisInfections and infestations | 3/44 | 3/34 | 0/15 | 4/24 | 0/26 | 5/53 | 2/24 | 2/27 | 1/52 | 0/26 | 2/27 | 2/27 | 4/22 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/44 | 1/34 | 0/15 | 0/24 | 0/26 | 0/53 | 0/24 | 0/27 | 2/52 | 0/26 | 0/27 | 0/27 | 4/22 |
| BacteraemiaInfections and infestations | 3/44 | 2/34 | 0/15 | 3/24 | 3/26 | 3/53 | 2/24 | 3/27 | 3/52 | 1/26 | 4/27 | 0/27 | 1/22 |
| PyrexiaGeneral disorders | 1/44 | 1/34 | 0/15 | 0/24 | 0/26 | 0/53 | 3/24 | 1/27 | 2/52 | 2/26 | 2/27 | 0/27 | 1/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/44 | 0/34 | 0/15 | 0/24 | 1/26 | 1/53 | 1/24 | 1/27 | 1/52 | 1/26 | 2/27 | 0/27 | 2/22 |
| AnaemiaBlood and lymphatic system disorders | 0/44 | 1/34 | 1/15 | 0/24 | 0/26 | 0/53 | 0/24 | 1/27 | 0/52 | 2/26 | 2/27 | 2/27 | 2/22 |
| Cardiac failure congestiveCardiac disorders | 0/44 | 0/34 | 0/15 | 0/24 | 0/26 | 0/53 | 0/24 | 0/27 | 0/52 | 0/26 | 0/27 | 1/27 | 2/22 |
| Event | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 9/44 | 2/34 | 4/15 | 3/24 | 3/26 | 15/53 | 9/24 | 12/27 | 18/52 | 14/26 | 12/27 | 11/27 | 14/22 |
| ConstipationGastrointestinal disorders | 8/44 | 6/34 | 2/15 | 5/24 | 9/26 | 22/53 | 12/24 | 14/27 | 32/52 | 5/26 | 6/27 | 10/27 | 12/22 |
| Injection site painGeneral disorders | 11/44 | 11/34 | 9/15 | 7/24 | 9/26 | 18/53 | 11/24 | 16/27 | 6/52 | 8/26 | 9/27 | 11/27 | 12/22 |
| DiarrhoeaGastrointestinal disorders | 22/44 | 11/34 | 2/15 | 6/24 | 9/26 | 28/53 | 10/24 | 12/27 | 31/52 | 7/26 | 15/27 | 10/27 | 7/22 |
| AnaemiaBlood and lymphatic system disorders | 11/44 | 8/34 | 5/15 | 6/24 | 6/26 | 28/53 | 11/24 | 10/27 | 14/52 | 15/26 | 13/27 | 11/27 | 13/22 |
| NauseaGastrointestinal disorders | 12/44 | 9/34 | 0/15 | 6/24 | 5/26 | 31/53 | 11/24 | 13/27 | 26/52 | 10/26 | 8/27 | 8/27 | 12/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 14/44 | 6/34 | 4/15 | 6/24 | 5/26 | 26/53 | 13/24 | 12/27 | 24/52 | 14/26 | 14/27 | 9/27 | 12/22 |
| HypokalaemiaMetabolism and nutrition disorders | 5/44 | 9/34 | 1/15 | 9/24 | 11/26 | 25/53 | 9/24 | 14/27 | 27/52 | 2/26 | 8/27 | 6/27 | 6/22 |
| Decreased appetiteMetabolism and nutrition disorders | 9/44 | 4/34 | 4/15 | 4/24 | 6/26 | 25/53 | 8/24 | 14/27 | 20/52 | 8/26 | 8/27 | 4/27 | 7/22 |
| HypomagnesaemiaMetabolism and nutrition disorders | 5/44 | 6/34 | 2/15 | 4/24 | 8/26 | 27/53 | 6/24 | 8/27 | 23/52 | 4/26 | 4/27 | 9/27 | 4/22 |
Efficacy data set included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.22 (36.7 to 86.1) | 64.90 (29.1 to 83.4) | 71.04 (51.4 to 84.6) | 55.83 (22.0 to 77.0) | 62.01 (30.0 to 81.7) | 58.86 (29.2 to 82.5) | 77.83 (62.0 to 92.5) | 78.46 (66.7 to 92.6) | 77.78 (66.4 to 92.3) | 71.61 (54.7 to 85.5) | 72.05 (51.9 to 88.7) | 68.38 (18.1 to 85.3) | 71.27 (63.8 to 84.5) | 68.94 (18.1 to 92.6) |
| Sex: Female, Male(Participants) | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 19 | 8 | 3 | 9 | 6 | 26 | 10 | 11 | 18 | 10 | 11 | 6 | 8 | 145 |
| Male | 25 | 26 | 12 | 15 | 20 | 27 | 14 | 16 | 34 | 16 | 16 | 21 | 14 | 256 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 3 | 5 | 3 | 5 | 2 | 0 | 1 | 0 | 2 | 3 | 1 | 29 |
| Not Hispanic or Latino | 42 | 32 | 12 | 19 | 23 | 48 | 22 | 27 | 51 | 26 | 25 | 24 | 21 | 372 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 0 | 2 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Black or African American | 2 | 3 | 1 | 4 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 16 |
| White | 39 | 31 | 14 | 18 | 21 | 44 | 23 | 24 | 50 | 25 | 25 | 25 | 22 | 361 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
Ran from Jan 2011 to primary completion in Jul 2016, 66 months.
Results were first posted in Jan 2025, 8 years 6 months after primary completion. A results delay was requested in May 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guadecitabine